Form 4: Nurix Therapeutics CSO Executes Sell-to-Cover Transaction

Chief Scientific Officer Gwenn Hansen sold 3,214 shares of Nurix Therapeutics to satisfy tax obligations related to RSU vesting.

Summary

• Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, Inc., acquired 8,608 shares through the vesting of Restricted Stock Units (RSUs).
• A total of 3,214 shares were sold at a weighted average price of $16.6453 to cover mandatory tax withholding obligations.
• The transactions were executed on April 30, 2026.
• Following these transactions, the reporting person maintains a direct beneficial ownership of 120,399 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was a mandatory administrative action related to tax obligations rather than a discretionary market move.

Positives

• The transaction was a non-discretionary 'sell-to-cover' event, indicating the executive remains invested in the company's long-term performance.
• The vesting of RSUs reflects the ongoing service and retention of key scientific leadership.

Negatives

• The sale of shares, even for tax purposes, reduces the total number of shares held by the executive.

Risks

• Reliance on equity-based compensation may be impacted by future volatility in the company's share price.
• The vesting of RSUs is contingent upon the continued provision of services to the issuer.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that sell-to-cover transactions are standard practice for biotech executives receiving equity compensation and do not typically signal a change in sentiment regarding the company's clinical or commercial prospects.

Comparison to Industry Standards

• The use of sell-to-cover transactions to satisfy tax obligations is a standard corporate governance practice among publicly traded biotechnology companies.
• The structure of the RSU vesting schedule (quarterly over three years) is consistent with industry norms for executive retention.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary and limited to tax coverage.

Next Steps

• Continued vesting of remaining RSUs according to the established three-year quarterly schedule.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Insider Trading, Form 4, Biotech, Equity Compensation, Tax Withholding